Prof. Thomas Müller
Department of Neurology
St. Joseph Hospital
Berlin-Weißensee, Germam
Email: th.mueller@alexius.de, thomas.mueller@ruhr-uni-bochum.de
Qualifications
2009 Consultant Neurology/Psychiatry, St Joseph Berlin Tempelhof
2002 Member of the Faculty, Neuroscience of the
Ruhr-University of Bochum
1996 Senior physician, University lecturer
Publications (Selected)
-
Placebo influences on dyskinesia in Parkinson's disease. Goetz CG, Laska
E, Hicking C, Damier P, Müller T, Nutt J, Olanow CW, Rascol O, Russ H.
Movement Disorders 2008; 23(5): 700-707.
-
Impact of endurance exercise on levodopa-associated cortisol release and
force increase in patients with Parkinson's disease. Müller T, Muhlack S.
Journal of Neural Transmission 2008; 115(6): 851-855.
-
A comprehensive genetic study of the proteasomal subunit S6 ATPase in
German Parkinson's disease patients. Wahl C, Kautzmann S, Krebiehl G, Strauss
K, Woitalla D, Müller T, Bauer P, Riess O and Krüger R. Journal of Neural
Transmission 2008; 115(8): 1141-1148.
-
Entacapone improves absorption of a co-administered salt in patients with
Parkinson’s disease. Müller T, Woitalla D, Goetze O, Erdmann C. Movement
Disorders 2008; 23(10): 1458-1461.
-
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with
advanced Parkinson disease and motor fluctuations: the ADVANS Study. Rascol O,
Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T,
Advance Study Group. Archives of Neurology 2008; 65(5): 577-583.
-
Protocol for German trial of Acyclovir and corticosteroids in
Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational,
randomized, double-blind, placebo-controlled German, Austrian and Dutch trial
[ISRCTN45122933]. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E,
Jensen K, Schielke E, Schmutzhard E, de Gans J, Chung CH, Luntz S, Hacke W,
Meyding-Lamadé U, and the GACHE Investigators. BMC Neurology 2008; 8: 40.
-
Increase of relapse rate during assisted reproduction technique in
patients with multiple sclerosis. Hellwig K, Schimrigk S, Beste C, Müller T,
Gold R. European Neurology 2009; 61(2): 65-68.
-
Cysteine elevation in Levodopa treated patients with Parkinson’s disease.
Müller T, Kuhn W. Movement Disorders 2009; 24(6): 929-932.
-
Effects of aging, Parkinson's disease, and dopaminergic medication on
response selection and control. Willemssen R, Falkenstein M, Schwarz M, Müller
T, Beste C. Neurobiology of Aging Epub 2009, DOI: 10.1016/j.neurobiolaging.2009.02.002.
-
Homocysteine levels after acute levodopa intake in patients with
Parkinson’s disease. Müller T, Kuhn W. Movement Disorders 2009; 24(9): 1339-1343.
-
Response monitoring in de novo patients with Parkinson's disease.
Willemsen R, Müller T, Schwarz M, Falkenstein M, Beste C. Plos One 2009; 4(3):
e4898.
-
Riluzole treatment, survival and diagnostic criteria in Parkinson plus
disorders: the NNIPPS study. Bensimon G, Ludolph A, Agid Y, Vildaihet M, Payan
C, Leigh PN, NNIPS Study Group. Brain 2009; 132: 156-171.
-
Peripheral COMT inhibition prevents levodopa associated homocysteine
increase. Müller T, Muhlack S. Journal of Neural Transmission 2009; 116(10):
1253-1256.
-
Tolcapone ist wirksam, sicher und gut vertrglich: eine offene,
beobachtende Studie. Müller T, Fischer G. Aktuelle Neurologie 2009; 36: 499-505.
-
Diadochokinetic movements differ between patients with Parkinson’s disease
and controls. Müller T, Harati A. Journal of Neural Transmission 2010; 117(2):
189-195.
-
Effect of exercise on reactivity and motor behavior in patients with
Parkinson’s disease. Müller T and Muhlack S. Journal of Neurology, Neurosurgery
& Psychiatry 2010; 81: 747-753.